Colchicine Use in Patients with COVID-19: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Dec 28

PMID 34962939

Citations 16

Authors

Leonard Chiu

Chun-Han Lo

Max Shen

Nicholas Chiu

Rahul Aggarwal

Jihui Lee

Young-Geun Choi

Henry Lam

Elizabeth Horn Prsic

Ronald Chow

Hyun Joon Shin

Affiliations

Soon will be listed here.

Abstract

Introduction: Colchicine may inhibit inflammasome signaling and reduce proinflammatory cytokines, a purported mechanism of COVID-19 pneumonia. The aim of this systematic review and meta-analysis is to report on the state of the current literature on the use of colchicine in COVID-19 and to investigate the reported clinical outcomes in COVID-19 patients by colchicine usage.

Methods: The literature was searched from January 2019 through January 28, 2021. References were screened to identify studies that reported the effect of colchicine usage on COVID-19 outcomes including mortality, intensive care unit (ICU) admissions, or mechanical ventilation. Studies were meta-analyzed for mortality by the subgroup of trial design (RCT vs observational) and ICU status. Studies reporting an risk ratio (RR), odds ratio (OR) and hazard ratio (HR) were analyzed separately.

Results: Eight studies, reporting on 16,248 patients, were included in this review. The Recovery trial reported equivalent mortality between colchicine and non-colchicine users. Across the other studies, patients who received colchicine had a lower risk of mortality-HR of 0.25 (95% CI: 0.09, 0.66) and OR of 0.22 (95% CI: 0.09, 0.57). There was no statistical difference in risk of ICU admissions between patients with COVID-19 who received colchicine and those who did not-OR of 0.26 (95% CI: 0.06, 1.09).

Conclusion: Colchicine may reduce the risk of mortality in individuals with COVID-19. Further prospective investigation may further determine the efficacy of colchicine as treatment in COVID-19 patients in various care settings of the disease, including post-hospitalization and long-term care.

Citing Articles

Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1.

Han H, Luo R, Long X, Wang L, Zhu Q, Tang X Elife. 2024; 13.

PMID: 38375778 PMC: 10878691. DOI: 10.7554/eLife.85985.

An Unusual Cause of Longstanding Diarrhea.

Peralta I, Hubbard E, Nodit L Cureus. 2024; 16(1):e52161.

PMID: 38344513 PMC: 10859108. DOI: 10.7759/cureus.52161.

Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses.

Danjuma M, Sayed R, Aboughalia M, Hassona A, Elsayed B, Elshafei M Heliyon. 2023; 9(10):e20155.

PMID: 37767472 PMC: 10520783. DOI: 10.1016/j.heliyon.2023.e20155.

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.

Ajmeera D, Ajumeera R Genes Dis. 2023; 11(1):148-175.

PMID: 37588226 PMC: 10425757. DOI: 10.1016/j.gendis.2022.12.013.

Strategies for the Management of Spike Protein-Related Pathology.

Halma M, Plothe C, Marik P, Lawrie T Microorganisms. 2023; 11(5).

PMID: 37317282 PMC: 10222799. DOI: 10.3390/microorganisms11051308.

References

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

Rodriguez-Nava G, Trelles-Garcia D, Yanez-Bello M, Chung C, Trelles-Garcia V, Friedman H . Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020; 24(1):429. PMC: 7358561. DOI: 10.1186/s13054-020-03154-4. View

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

Slobodnick A, Shah B, Pillinger M, Krasnokutsky S . Colchicine: old and new. Am J Med. 2015; 128(5):461-70. PMC: 4684410. DOI: 10.1016/j.amjmed.2014.12.010. View

Jose R, Manuel A . COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020; 8(6):e46-e47. PMC: 7185942. DOI: 10.1016/S2213-2600(20)30216-2. View

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View

Scarsi M, Piantoni S, Colombo E, Airo P, Richini D, Miclini M . Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020; 79(10):1286-1289. PMC: 7509521. DOI: 10.1136/annrheumdis-2020-217712. View

Mareev V, Orlova Y, Plisyk A, Pavlikova E, Akopyan Z, Matskeplishvili S . Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study. Kardiologiia. 2021; 61(2):15-27. DOI: 10.18087/cardio.2021.2.n1560. View

10.

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

11.

Stewart S, Yang K, Atkins K, Dalbeth N, Robinson P . Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020; 22(1):28. PMC: 7020579. DOI: 10.1186/s13075-020-2120-7. View

12.

Brunetti L, Diawara O, Tsai A, Firestein B, Nahass R, Poiani G . Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J Clin Med. 2020; 9(9). PMC: 7565543. DOI: 10.3390/jcm9092961. View

13.

Nieto-Torres J, Verdia-Baguena C, Jimenez-Guardeno J, Regla-Nava J, Castano-Rodriguez C, Fernandez-Delgado R . Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015; 485:330-9. PMC: 4619128. DOI: 10.1016/j.virol.2015.08.010. View

14.

Vrachatis D, Giannopoulos G, Giotaki S, Raisakis K, Kossyvakis C, Iliodromitis K . Impact of colchicine on mortality in patients with COVID-19: A meta-analysis. Hellenic J Cardiol. 2021; 62(5):374-377. PMC: 7833703. DOI: 10.1016/j.hjc.2020.11.012. View

15.

Tomazini B, Maia I, Cavalcanti A, Berwanger O, Rosa R, Veiga V . Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020; 324(13):1307-1316. PMC: 7489411. DOI: 10.1001/jama.2020.17021. View

16.

Sandhu T, Tieng A, Chilimuri S, Franchin G . A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. Can J Infect Dis Med Microbiol. 2020; 2020:8865954. PMC: 7588830. DOI: 10.1155/2020/8865954. View

17.

Goldman J, Lye D, Hui D, Marks K, Bruno R, Montejano R . Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020; 383(19):1827-1837. PMC: 7377062. DOI: 10.1056/NEJMoa2015301. View

18.

Angus D, Buzgau A, Cheng A, Higgins A, Hullegie S, Lawler P . Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020; 324(13):1317-1329. PMC: 7489418. DOI: 10.1001/jama.2020.17022. View

19.

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

20.

Deftereos S, Giannopoulos G, Vrachatis D, Siasos G, Giotaki S, Gargalianos P . Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020; 3(6):e2013136. PMC: 7315286. DOI: 10.1001/jamanetworkopen.2020.13136. View